BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20443718)

  • 1. Hypertension in women: the role of progesterone and aldosterone.
    Boschitsch E; Mayerhofer S; Magometschnigg D
    Climacteric; 2010 Aug; 13(4):307-13. PubMed ID: 20443718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH
    Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menopause and cardiovascular disease: the evidence.
    Rosano GM; Vitale C; Marazzi G; Volterrani M
    Climacteric; 2007 Feb; 10 Suppl 1():19-24. PubMed ID: 17364594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
    Oelkers W
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():19-26; discussion 42-3. PubMed ID: 12659403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
    Oelkers W
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of controlling blood pressure.
    MacGregor GA; He FJ
    Climacteric; 2005 Oct; 8 Suppl 3():13-8. PubMed ID: 16203651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism.
    Palacios S; Foidart JM; Genazzani AR
    Maturitas; 2006 Nov; 55(4):297-307. PubMed ID: 16949774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
    Preston RA; White WB; Pitt B; Bakris G; Norris PM; Hanes V
    Am J Hypertens; 2005 Jun; 18(6):797-804. PubMed ID: 15925739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of different progestogens: the special case of drospirenone.
    Sitruk-Ware R
    Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.
    White WB; Pitt B; Preston RA; Hanes V
    Circulation; 2005 Sep; 112(13):1979-84. PubMed ID: 16186434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Added benefits of drospirenone for compliance.
    Foidart JM
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
    Simoncini T; Genazzani AR
    Climacteric; 2010 Feb; 13(1):22-33. PubMed ID: 19938948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender and the renin-angiotensin-aldosterone system.
    Komukai K; Mochizuki S; Yoshimura M
    Fundam Clin Pharmacol; 2010 Dec; 24(6):687-98. PubMed ID: 20608988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The renin-aldosterone system and drospirenone.
    Oelkers W
    Gynecol Endocrinol; 2002 Feb; 16(1):83-7. PubMed ID: 11915587
    [No Abstract]   [Full Text] [Related]  

  • 15. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen.
    Foidart JM; Faustmann T
    Gynecol Endocrinol; 2007 Dec; 23(12):692-9. PubMed ID: 18075844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
    Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
    Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers.
    Oelkers W; Helmerhorst FM; Wuttke W; Heithecker R
    Gynecol Endocrinol; 2000 Jun; 14(3):204-13. PubMed ID: 10923282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide.
    Preston RA; Norris PM; Alonso AB; Ni P; Hanes V; Karara AH
    Menopause; 2007; 14(3 Pt 1):408-14. PubMed ID: 17224857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Renin-angiotensin-aldosterone system and natriuretic peptide system--reference to cardiovascular diseases].
    Yasue H; Mizuno Y; Harada E; Ito T
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():164-9. PubMed ID: 15506362
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.